Fig. 3From: 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatmentExpanded Prostate Cancer Index Composite-26 (EPIC-26)Back to article page